Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Revise Assessment Scheme for Deaths after COVID Shots: MHLW Panel Members
December 28, 2022
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Japan’s Drug Production Contracts 0.9% to 9.2 Trillion Yen in 2021: MHLW
December 28, 2022
- PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- 1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
December 27, 2022
- Funding for Drug Supply Info System Nixed for 2nd Year: FY2023 Budget
December 27, 2022
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Chuikyo Recommends Add-On Fee Premiums Related to Drug Supply Issues
December 26, 2022
- PMDA to Add 4 Staff to Expand Orphan Designation Program: FY2023 Budget
December 26, 2022
- MHLW’s FY2023 Budget Totals 33.2 Trillion Yen
December 26, 2022
- Japan Cabinet OKs Record Social Security Budget for FY2023
December 26, 2022
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan’s Reform Timeline Sees Major Updates for Text on Drug Pricing Overhaul
December 23, 2022
- Japan Deregulation Panel Proposes Two-Step Approval Scheme for SaMD
December 23, 2022
- PMDA to Develop Overseas PR Strategy to Woo Overseas Biotechs
December 23, 2022
- MHLW to Issue Development Requests for New Indications for 6 Meds including Stivarga
December 23, 2022
- Chuikyo Reps in Face-Off over Medical Fees to Address Drug Supply Disruptions
December 22, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…